Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BANTING
- Sponsors Amgen
- 25 Sep 2020 Results (n=1402) of pooled analysis of two trials BANTING and BERSON assessing achievement of ESC/EAS lipid treatment goals with evolocumab in patients with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Sep 2020 Results of pooled analysis of two trials BANTING and BERSON assessing evaluate the achievement of lipid treatment goals with evolocumab vs placebo in T2D presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 05 Apr 2019 Results published in the Diabetologia